- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00444314
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
Phase II Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion Alone and in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma Progressing on Sunitinib Malate
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University School of Medicine
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have a histologically confirmed renal cell cancer with a component of clear cell carcinoma and evidence of metastasis (pure sarcomatoid variant cancers and collecting duct malignancies will be excluded).
- Patients must have measurable disease, defined as at least one target lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 2 times the slice width with spiral CT scan (i.e. 10 mm if the CT slice width is 5 mm, 14 mm if the CT slice width is 7 mm).
Patients must have previously received or be currently receiving sunitinib malate (Sutent) with evidence of disease progression while receiving sunitinib malate (as evident by new lesions on CT/MRI/bone scan or unequivocal growth in measurable tumor lesions).
Note: Patients will be stratified to:
A: Patients previously treated with sunitinib malate. At least 4 week washout since last treatment administered is required before patient is eligible for study. Once patients meet all other eligibility criteria, they will be treated with Panzem® NCD alone.
B: Patients currently still on sunitinib. Patients will continue to receive their current dose/schedule of sunitinib. Once eligibility determined, patients will be started on Panzem® NCD concurrently with their sunitinib. No drug washout of sunitinib malate is required for this stratification.
Note: Enrollment to the individual stratification will stop once that stratification has met its accrual goal.
- Age greater than or equal to 18 years.
- Life expectancy of greater than 3 months.
- ECOG performance status 0-2 (see Appendix A).
Patients must have normal organ and marrow function as defined below:
- leukocytes greater than or equal to 3,000/μL
- absolute neutrophil count greater than or equal to 1,200/μL
- hemoglobin greater than or equal to 9.0 g/dl (patient may be transfused to this level)
- platelets greater than or equal to 100,000/μL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT)less than or equal to 2.5 X institutional upper limit of normal
- creatinine less than or equal to 1.5 x institutional upper limit of normal
- Adequate cardiac function by history. If the patient has any history of cardiac disease (prior myocardial infarction, congestive heart failure, etc.), a normal echocardiogram or multigated acquisition (MUGA) scan will be required (LVEF greater than or equal to institutional lower limit of normal).
- No evidence for uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The systolic blood pressure must be less than or equal to 140 mmHg and the diastolic blood pressure less than or equal to 90 mmHg. Patients are allowed to be on anti-hypertensive medications.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- No major surgery, radiotherapy, chemotherapy, cytokine therapy or other experimental therapy is permitted within 4 weeks of treatment initiation. Patients must recover to baseline or grade 1 from any clinically significant adverse event experienced during those prior therapies.
- Patients may not be concurrently receiving any other investigational agents while participating on this study.
- Patients with active brain metastases are excluded. Previously treated brain metastasis will be allowed provided that the patient is clinically stable (off systemic steroids and not on antiepileptic agents) with a repeat imaging study (within 4 weeks of registration) of the brain confirming stable CNS disease. Patients with known CNS carcinomatosis or leptomeningeal spread of their disease will be excluded from this study due to their poor prognosis.
- Patients with gastrointestinal abnormalities including inability to take oral medications, requirement for intravenous alimentation, and malabsorption syndromes will be excluded.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-dependent diabetes or a fasting blood glucose of more than 10 mmol/L (200 mg/dL) will be excluded due to difficulty evaluating the tumor metabolic activity using FDG-PET.
- History of myocardial infarction or hospitalization for congestive heart failure within 12 months of enrollment.
- History of prior malignancy (except basal cell carcinoma resected with curative intent) unless resected or treated with curative intent, and disease free for greater than or equal to 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
NCD suspension, 1500 mg TID daily for 6 week cycles
|
Experimental: B
|
NCD suspension, 1500 mg TID daily for 6 week cycles
Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the objective response rate of Panzem NCD alone and in combination with Sunitinib Malate
Time Frame: Throughout study participation
|
Throughout study participation
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- ME-CLN-008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
-
iOMEDICO AGNovartis PharmaceuticalsCompletedCarcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell CarcinomaGermany
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedMetastatic Renal Cell Carcinoma | Metastatic Kidney CancerFrance
-
National Cancer Institute (NCI)RecruitingStage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditionsUnited States, Puerto Rico
-
Duke UniversityCompletedMetastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
-
Prometheus LaboratoriesCompletedMetastatic Renal Cell Carcinoma | Metastatic MelanomaUnited States
Clinical Trials on Panzem® NCD
-
CASI Pharmaceuticals, Inc.CompletedProstate CancerUnited States
-
CASI Pharmaceuticals, Inc.CompletedOvarian CancerUnited States
-
CASI Pharmaceuticals, Inc.CompletedRecurrent Glioblastoma MultiformeUnited States
-
University of Illinois at Urbana-ChampaignAmericares; Royal Health Awareness SocietyCompletedHypertension | Diabetes | Mental StressJordan
-
P.L.Shupik National Medical Academy of Post-Graduate...CompletedObesity | Overweight | Life Style
-
P.L.Shupik National Medical Academy of Post-Graduate...CompletedObesity | Overweight | Lipid Metabolism Disorders | Life Style | Men
-
CASI Pharmaceuticals, Inc.CompletedCarcinoid TumorUnited States
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompletedCardiovascular Diseases | Diabetes Mellitus, Type 2 | Antiretroviral Therapy, Highly ActiveSouth Africa
-
PossibleNyaya Health Nepal; Ministry of Health and Population, NepalWithdrawnHypertension | Diabetes Mellitus, Type 2 | Chronic Obstructive Pulmonary Disease | Noncommunicable DiseasesNepal
-
CASI Pharmaceuticals, Inc.CompletedRelapsed Multiple Myeloma | Plateau Phase Multiple MyelomaUnited States